DR-147 An exploratory study on the prognostic and predictive value of the immune infiltrate in metastastic bladder cancer and its relation with other microenvironmental factors and long non-coding RNAs.
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-147 An exploratory study on the prognostic and predictive value of the immune infiltrate in metastastic bladder cancer and its relation with other microenvironmental factors and long non-coding RNAs.
In urothelial cancer, prognosis and responsiveness to treatments, such as chemotherapy and checkpoint inhibitors, differs substantially between patients. Although urothelial …
DR-146 Treatment with targeted therapy based on genetic profiling by whole genome sequencing in patients with solid tumours
In the past two decades, the exploration of molecular mechanisms and genetic information in cancer led to the new approaches …
DR-145 Immune and stromal gene expression signature in metastatic prostate and breast cancer
The main reason that cancer is lethal lies in its ability to spread in the body, a process called metastasis. …
DR-142 Genomic landscape of non-small cell lung cancer (NSCLC) tumors and metastases.
Despite the advancements in lung cancer treatment in the last decades, most patients diagnosed with non-small cell lung cancer (NSCLC), …
DR-141 Driver mechanisms and regional mutation rates in the non-coding cancer genome
Cancer is caused by mutations that occur over time via genetic and environmental exposures. Some mutations called drivers unlock oncogenic …
DR-140 Landscape of cooperative interactions between germline and somatic events in cancer
In this project we will investigate to what extent the cooperation of inherited polymorphisms within regulatory regions and somatic aberration …
DR-139 Personalized OncoGenomics: A comprehensive pan-cancer analysis
The Personalized OncoGenomics (POG) Program sequences cancers from patients with advanced and metastatic tumours to determine which therapies are most …
DR-138 Genomic identification and expression of oncogenic FGFR2 structural variants.
Using mouse models, we found certain variants of the fibroblast growth factor receptor 2 gene (Fgfr2) to be strong tumor …
DR-137 HEcoPerMed (Healthcare- and pharma-economics in support of the International Consortium for Personalised Medicine)
HecoPerMed seeks to improve health economic models for personalized medicine, both payment models and evaluation (HTA) models. We seek to …
DR-136 Tracking cancer evolution from emergence to metastasis
We plan to investigate the evolution of lung tumours at different stages of cancer development. The molecular data used to …
DR-134 The immunogenic potential of recurrent cancer drug resistance mutations: an in silico study
Targeted cancer therapies can be remarkably effective but a considerable number of patients develop resistance as treatment proceeds. Resistance can …
DR-133 Pan-cancer investigation of cancer evolution and tumour evolutionary trajectories
Cancer is a complex disease, characterized by a wide spectrum of genome abnormalities. We aim to describe the order and …
Een complete DNA-test biedt bij patiënten met PTO de extra mogelijkheid om erachter te komen waar de kanker is begonnen. Hierdoor wordt vaak de primaire tumor toch gevonden. Daarnaast geeft de test vaak aanknopingspunten voor een gerichte behandeling.